MANUSCRIPT_ ENGLISH Qol coping
Demographic, behavioral, clinical, and laboratory data were described by absolute and relative frequencies, or by means and standard deviations according to their classification. Associations between the variables of interest and adherence were assessed using the Chi-square test. The comparison of continuous quantitative variables, such as quality of life and coping strategies, regarding the adherence, was obtained using the Student's t-test, if the distributions were symmetric, or the non-parametric Manny-Whitney test, if they were not. Normality was verified through the Kolmogorov-Smirnov test. The independent effect of the variables on adherence was evaluated through a multivariate logistic regression model by the Backward Stepwise RL method. It ran as input variables those with a p-value <0.20 in the univariate analysis. The adequacy of the model was verified by the Hosmer-Lemeshow test (p> 0.05). The results were presented as adjusted odds ratio (aj.OR), with their respective 95% confidence interval (95% CI). The definitive model was accepted after all adjustment criteria were met. We used univariate logistic regression to estimate the probability of the adherence variable may occur due to the pharmaceutical intervention. All analyzes were performed using the statistical program SPSS version 26 (IBM®), and the significance level was set at 5%.
Steps to reproduce
A semi-structured questionnaire comprised data on sociodemographic (gender, age, skin color/ethnicity, marital status, schooling level, monthly income, employment status, living with family), behavioral (sexual orientation, alcohol use, illicit drug use, smoking, physical activity, religious practice, hobbies), and clinical aspects (mode of transmission, previous allergic conditions, preexisting diseases, previous visual impairment). The questionnaire was applied through a face-to-face interview before the start of ART. Laboratory data (HIV viral load, CD4 count) were accessed using the Laboratory Test Control System (SISCEL). Information about baseline clinical condition, existing opportunistic infection, associated sexually transmitted infection (STI), and therapeutic scheme, were obtained from the patient´s medical record. The social indicators of quality of life (QoL) and coping strategies were measured twice: after 12 months and after 24 months of follow up. QoL was assessed by the WHOQOL-HIV BREF instrument of the World Health Organization.Coping strategies were assessed by the Brazilian version of the Ways of Coping Scale.In this study, the adherence barrier was defined as an issue from the patient´s point of view that could directly affect the ART taking. In this study, the situations identified as potential adherence barriers were the difficulty of access to ART, self-perception of risk, lack of family support, disturbance of daily routine, the status of physical well-being, the status of psychological well-being, lack of autonomy in the ART intake, and adverse reactions. Except for this last one, which was measured in the first six months and after 12 months of ART use, the other variables were measured twice, after 12 months and 24 months of follow-up, through face-to-face interviews during the pharmaceutical appointments.